Get the Weekly Intelligence Brief — top committee picks every Sunday.
BAX · NYSE · STOCK

Baxter International (BAX) Stock Analysis

Healthcare Updated August 25, 2026
$26.49
52W $15.73 – $30.00
53/100
$13.62B
-12.9
0.59
AI Committee Verdict
Watch
53/100
Conviction: Contested · 33% agreement · 6 analysts
+21.5%
-0.3%
67.16:1
Contested

Is BAX Bullish or Bearish?

Mixed. Innellis AI committee rates Baxter International (BAX) Watch with a composite score of 53/100 , based on 6 analysts with 33% agreement. Last updated August 25, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.36 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.64 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.55) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • Dividend yield of 3.2% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
  • ROE of only -16.6% -- cheap may mean cheap for a reason — Value
  • Debt-to-equity of 1.55 adds balance-sheet risk to the value case — Value
  • MACD histogram negative -- bearish momentum — Technical
  • High leverage (debt-to-equity 1.55) amplifies downside in a stress scenario — Risk
  • Bollinger bandwidth of 18.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of August 25, 2026
Overall Committee Score
53/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 82%
of 192 Healthcare peers
Value Analyst bearish
40 / 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 3.2% pays you to wait
− ROE of only -16.6% -- cheap may mean cheap for a reason
Growth Analyst bullish
62 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst neutral
58 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
32 / 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.55) amplifies downside in a stress scenario
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3063.01)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 52.6 to 52.6.

Comparing 2026-08-24 to 2026-08-25 (1 day apart).

Technical Analysis

RSI (14)
49.5
Neutral
MACD Histogram
-0.283
Bearish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$26.25
Resistance
$32.00
Bollinger %B
0.46
Inside Bands
Price vs Moving Averages
EMA 9
$26.50 Below
EMA 21
$25.94 Above
EMA 50
$24.02 Above
EMA 200
$21.91 Above

Fundamental Analysis

Valuation
96
Growth
69
Profitability
6
Financial Health
71
Cash Flow
70
Valuation
P/E Ratio -12.9×
P/B Ratio 2.19×
PEG Ratio 0.16
Dividend Yield 0.76%
52W High $30.00
52W Low $15.73
Quality & Growth
ROE -1561.4%
ROA -477.2%
Gross Margin 3007.8%
Operating Margin -238.9%
Revenue Growth YoY
Debt / Equity 1.56
AI Fundamental Assessment
P/E ratio of -12.9 (inexpensive relative to a 15-40x range); Price-to-book of 2.2x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -15.6%; Return on assets of -4.8%; Net margin of -9.3%; Gross margin of 30.1%; Current ratio of 1.95 (healthy short-term liquidity); Debt-to-equity of 1.56; Free cash flow per share is positive (1.31); Most recent quarter beat estimates by 51.5%; 2 consecutive earnings beats; EPS growth accelerating (-18.2% -> +55.6% QoQ); Average YoY EPS growth of -5.1%; Analyst estimates falling over recent quarters
Get the Full BAX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime